Quick Summary
- Positive Phase 1 MAD Results: Statistically significant body weight reductions vs. placebo across multiple dose cohorts, validating the amylin receptor pathway.
- Differentiated Tolerability Profile: Lower nausea burden vs. GLP-1 comparators addresses the #1 adherence barrier in the obesity drug class.
- Phase 2 Advancement Planned: AbbVie intends to move into a Phase 2 dose-ranging study, a key pipeline milestone for its cardiometabolic franchise.
AbbVie (NYSE: ABBV) announced on March 9, 2026, positive topline results from a Phase 1 multiple ascending dose (MAD) study evaluating ABBV-295 the company’s investigational long-acting amylin analog in adults with overweight or obesity.
The results confirm that ABBV-295 achieves statistically significant reductions in body weight compared to placebo, while demonstrating a differentiated and favorable tolerability profile. This combination is particularly compelling in a competitive obesity therapeutics market increasingly dominated by GLP-1 receptor agonists, where gastrointestinal side effects remain the primary driver of patient discontinuation.
The announcement marks a significant milestone for AbbVie’s emerging cardiometabolic pipeline, positioning ABBV-295 as a potential best-in-class or first-in-class asset leveraging the amylin pathway a mechanism of action entirely distinct from the GLP-1/GIP pathways exploited by semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound).
Background: The Amylin Pathway
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. It plays a crucial, multifaceted role in regulating postprandial physiology and has long been recognized as a pharmacologically rich target for metabolic disease.
Key physiological roles relevant to ABBV-295:
- Central satiety signaling via area postrema and nucleus of the solitary tract is independent of GLP-1 pathways.
- Appetite suppression reduces meal-initiated food intake through distinct hypothalamic circuits.
- Gastric emptying modulation to dampen postprandial glucose excursions.
- Glucagon suppression during meals contributes to glycemic control.
- Synergy with GLP-1 agonists when co-administered, suggesting a compelling combination therapy potential.
Despite this validated biology, the development of amylin-based therapies has historically been hampered by aggregation propensity, a formulation challenge that limited the original amylin analog pramlintide (Symlin) to short-acting, multiple-daily-injection regimens with modest efficacy. ABBV-295 represents a next-generation long-acting amylin analog engineered to overcome these barriers through novel molecular stabilization, enabling once-weekly subcutaneous administration.
Read More: AbbVie Reports Breakthrough Results for RINVOQ® (Upadacitinib) in Alopecia Areata Treatment
Phase 1 MAD Study: Design
The Phase 1 MAD study was a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of ABBV-295 in adult participants with overweight or obesity (BMI ≥27 kg/m²).
The MAD design involving repeated doses at sequentially higher levels with safety review between cohorts is the gold-standard methodology for establishing a safe and efficacious dose range prior to Phase 2 dose-selection trials. It informs maximum tolerated dose (MTD), no-observed-adverse-effect level (NOAEL), and optimal pharmacological dose (OPD) determinations.
Study objectives:
- Primary: Safety and tolerability of ABBV-295 across multiple ascending dose levels
- Secondary: PK/PD characterization following once-weekly subcutaneous dosing
- Exploratory: Effect of ABBV-295 on body weight and key cardiometabolic biomarkers
Clinical Data Summary
| Parameter | Finding | Clinical Significance |
|---|---|---|
| Study Design | Phase 1, Randomized, Double-blind, Placebo-controlled MAD | Gold-standard early-phase design; minimizes bias |
| Molecule | ABBV-295 — long-acting amylin analog (weekly SC injection) | Once-weekly dosing improves adherence vs. daily injectables |
| Population | Adults with overweight/obesity (BMI ≥27 kg/m²) | Broad phenotype; real-world commercial relevance |
| Primary Endpoint | Safety, tolerability & PK/PD profile | Foundation for Phase 2 dose selection |
| Weight Reduction | Statistically Significant vs. placebo across dose cohorts | Validates amylin pathway as viable obesity target in humans |
| Tolerability | Favorable; GI AEs mild-to-moderate, transient | Differentiated from GLP-1 receptor agonist class profile |
| Nausea | Lower relative nausea vs. GLP-1 comparators (historical) | Addresses #1 adherence barrier in obesity drug class |
| SAEs | None Attributed to ABBV-295 | Supports dose escalation and Phase 2 entry |
| Biomarkers | Improvements in fasting glucose & lipid parameters (exploratory) | Signals cardiometabolic benefit beyond weight reduction |
| Dosing | Once-Weekly SC | Competitive with semaglutide and tirzepatide convenience |
| Next Steps | Phase 2 dose-ranging study planned | Accelerated development timeline supported by robust Phase 1 package |
Key Efficacy Findings
The centerpiece of AbbVie’s announcement was the achievement of statistically significant body weight reduction versus placebo across multiple dose cohorts, a result not universally expected from a Phase 1 MAD study, which is primarily powered for safety rather than efficacy.
This early efficacy signal meaningfully de-risks the clinical development program and provides confidence in the biological activity of ABBV-295 in humans. The dose-dependent relationship between ABBV-295 exposure and weight loss suggests a robust pharmacodynamic effect consistent with amylin-mediated satiety mechanisms.
Cardiometabolic biomarker improvements:
Beyond weight reduction, exploratory analyses pointed to improvements in fasting glucose and lipid parameters indicating potential cardiometabolic benefits that could strengthen labeling and commercial positioning if confirmed in Phase 2/3 trials.
PK/PD profile
ABBV-295 demonstrated a pharmacokinetic profile consistent with once-weekly dosing, with an exposure-response relationship that supports dose selection for Phase 2 development. The long-acting formulation technology appears to have successfully addressed the aggregation challenges that limited prior amylin analogs.
Read More: New anti-obesity drugs reduces weight-loss surgery numbers
Tolerability: The Key Differentiator
In the obesity therapeutics market, tolerability, particularly gastrointestinal tolerability, is increasingly recognized as a critical driver of real-world adherence and commercial success. GLP-1 receptor agonists, while highly effective, carry high rates of nausea, vomiting, and constipation that limit dose escalation and drive discontinuation in a meaningful proportion of patients.
ABBV-295’s Phase 1 MAD data revealed a tolerability profile that may represent a genuine clinical and commercial differentiator:
- GI adverse events were generally mild-to-moderate in severity and transient in nature.
- Nausea rates appeared lower relative to historical GLP-1 comparators at equivalent efficacy dose ranges.
- No serious adverse events attributed to ABBV-295 were reported in the topline data.
- The safety profile was consistent across dose cohorts, supporting dose escalation into Phase 2.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Development Pathway
Following the positive Phase 1 MAD results, AbbVie has indicated its intention to advance ABBV-295 into a Phase 2 dose-ranging study. The Phase 2 program will be designed to:
- Confirm dose-response relationships for weight loss and metabolic endpoints in a larger, more representative population
- Evaluate long-term safety and tolerability over extended treatment duration (typically 16–52 weeks)
- Explore ABBV-295 in combination with GLP-1 receptor agonists to assess additive or synergistic efficacy
- Identify target patient populations, particularly those intolerant to or inadequately responding to existing GLP-1 therapies
Subject to Phase 2 results, the program could advance to pivotal Phase 3 trials targeting regulatory submission by the late 2020s. The strong Phase 1 data package supports an expedited development timeline, and AbbVie’s commercial infrastructure, built over decades of blockbuster drug launches, provides a meaningful go-to-market advantage should ABBV-295 reach approval.
Last Modified:
